Oncimmune is not the only company looking to use the immune system to diagnose cancer. But its growth plans are intense, and it intends to prove the economic benefits of…
In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
Transvaginal mesh implants are banned in the US, but remain a possibility in Europe.
Second Sight’s second product might lead the company to second place in the market.
A tiny Israeli company has beaten some of the biggest medtechs in the world to the wireless charging of heart pumps.
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
With one cancer blood test established on the market Guardant is starting down the road to validating another – this time as a screening assay.
The battle for dominance of the transcatheter aortic valve market has shifted to new territory. And once again, Edwards Lifesciences is winning.
Another vast trial is on the cards for Apple’s ECG, and ought to yield more meaningful data.